MedImmune And National Institutes Of Health Begin Clinical Testing Of A Live, Attenuated Intranasal Vaccine Against An H5N1 Avian Influenza Virus
submited by kickingbird at Jun, 16, 2006 16:18 PM from Medical News Today
MedImmune, Inc.(Nasdaq: MEDI) announced today that the National Institutes of Health (NIH)has begun enrolling participants in a Phase 1 study of an intranasal H5N1influenza vaccine candidate based on the company´s live, attenuated vaccinetechnology. [click link for full article]
See Also:
Latest news in those days:
- China: Two human cases of avian influenza A(H9N2) reported in Guangdong Province and Hunan Province, one human case of avian influenza A(H10N3) reported in Guangdong Province 1 days ago
- GISAID: H5N1 Bird Flu continues to circulate in the United States 3 days ago
- Canada: Highly pathogenic avian influenza in Nova Scotia, February 4, 2026 5 days ago
- UK: Bird flu (avian influenza): latest situation in England 12 days ago
- US: Highly Pathogenic Avian Influenza Detected in Ottawa County Backyard Flock in Michigan 14 days ago
[Go Top] [Close Window]
